EMA Application withdrawn: Idhifa — Celgene Europe BV

View source ↗

Summary

EMA withdrawn the application for Idhifa (benzenedicarboxamide?) by Celgene Europe BV; therapeutic area Leukemia, Myeloid, Acute.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia Myeloid Acute

Drugs mentioned

• IDHIFA (enasidenib)

Snippet

Status: Application withdrawn. Therapeutic area: Leukemia, Myeloid, Acute. MAH: Celgene Europe BV